GSK plc (LSE/NYSE: GSK) announced on 17 November 2026 that the US Food and Drug Administration has granted accelerated approval to Nelkarmi (neladalkib) for adults with locally advanced or metastatic ALK-positive non-small cell lung cancer who have previously received specified ALK tyrosine kinase inhibitor therapy. The approval arrived ahead of the FDA's original target action date of 27 November 2026 and marks GSK's second lung cancer medicine approved in 2026, following Jideytro in July. Investors will note that Nelkarmi originates from GSK's acquisition of Nuvalent, Inc, and is already being evaluated in an ongoing phase III trial in treatment-naïve patients.
Key Points
- GSK plc (LSE/NYSE: GSK) — global biopharma company headquartered in London
- FDA grants accelerated approval to Nelkarmi (neladalkib) for pretreated ALK-positive NSCLC ahead of the 27 November 2026 target action date
- ALKOVE-1 trial confirmed ORR of 49% in alectinib-pretreated patients and 32% in patients with two or more prior ALK TKIs plus chemotherapy
- Investors should watch progress of the ALKAZAR phase III trial in TKI-naïve ALK-positive NSCLC, which could support a broader future label
ALKOVE-1 Trial Data Supporting FDA Approval of Neladalkib
The accelerated approval is based on results from the global single-arm phase I/II ALKOVE-1 trial, which enrolled 700 patients with ALK-positive solid tumours. The primary efficacy analysis included 222 patients with previously treated ALK-positive NSCLC. For patients who had received alectinib as their sole prior ALK TKI, the confirmed overall response rate was 49%, with responses lasting six months or more in 76% of responders and twelve months or more in 52%. For patients with two or more prior ALK TKIs and chemotherapy, the ORR was 32%, with six-month durability in 69% of responders and twelve-month durability in 51%.
Nelkarmi's Blood-Brain Barrier Penetration and Intracranial Response Rates
A distinctive design feature of Nelkarmi is its ability to cross the blood-brain barrier, addressing a clinically significant challenge in ALK-positive NSCLC, which frequently metastasises to the central nervous system. Among patients with measurable CNS metastases at baseline, intracranial ORR reached 55% — including 25% complete responses — in alectinib-pretreated patients. In those who had received two or more prior ALK TKIs and chemotherapy, intracranial ORR was 26%, including 11% complete responses. The announcement states that ALK-positive patients are often younger and can remain on treatment for years, making tolerability a particular concern in this population.
Safety Profile and Hepatotoxicity as the Primary Discontinuation Risk
The most common adverse reactions occurring in 20% or more of patients included hepatotoxicity, musculoskeletal pain, constipation, dysgeusia, peripheral neuropathy, oedema, and fatigue. Permanent discontinuation due to adverse reactions occurred in 5% of patients, with hepatotoxicity cited as the most frequent cause. This safety signal represents a company-specific risk that prescribers and investors will monitor as real-world use expands beyond the controlled trial setting.
Nuvalent Acquisition and the Ongoing ALKAZAR Phase III Trial
Nelkarmi is part of the portfolio acquired through GSK's purchase of Nuvalent, Inc, and its approval represents the commercial realisation of that deal in a meaningful oncology segment. The medicine is currently being evaluated in ALKAZAR, an ongoing phase III trial targeting TKI-naïve ALK-positive NSCLC patients, which could support a significantly broader label if successful. GSK also received FDA Breakthrough Therapy and Orphan Drug designations for neladalkib prior to this approval, designations that reflect the unmet need in this genetically defined lung cancer subgroup.




Please wait processing your request...